Stay updated with breaking news from Nasdaq Srpt. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Sarepta Therapeutics (NASDAQ:SRPT – Get Free Report) had its target price dropped by equities research analysts at Royal Bank of Canada from $155.00 to $151.00 in a research note issued to investors on Thursday, Benzinga reports. The brokerage currently has an “outperform” rating on the biotechnology company’s stock. Royal Bank of Canada’s price objective points […]
Capula Management Ltd bought a new position in Sarepta Therapeutics, Inc. (NASDAQ:SRPT – Free Report) in the third quarter, according to its most recent disclosure with the SEC. The firm bought 11,627 shares of the biotechnology company’s stock, valued at approximately $1,409,000. Other hedge funds and other institutional investors have also modified their holdings of […]
Eagle Health Investments LP raised its holdings in Sarepta Therapeutics, Inc. (NASDAQ:SRPT – Free Report) by 79.0% during the third quarter, Holdings Channel reports. The institutional investor owned 174,212 shares of the biotechnology company’s stock after buying an additional 76,872 shares during the period. Sarepta Therapeutics makes up about 4.7% of Eagle Health Investments LP’s […]
Eagle Health Investments LP grew its stake in shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT – Free Report) by 79.0% during the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 174,212 shares of the biotechnology company’s stock after buying an additional 76,872 […]
Sarepta Therapeutics, Inc. (NASDAQ:SRPT – Free Report) – Investment analysts at Zacks Research lifted their FY2023 earnings per share estimates for shares of Sarepta Therapeutics in a research note issued to investors on Tuesday, January 2nd. Zacks Research analyst S. Ganoria now expects that the biotechnology company will earn ($6.77) per share for the year, […]